Meredith M. Regan, ScD, Harvard Medical School, Boston, MA, discusses the unknown benefit of chemotherapy in premenopausal woman currently under investigation in SOFT (NCT00066690) and TEXT (NCT00066703). Dr. Regan highlights the possible requirement for younger premenopausal woman to undergo ovarian function suppression (OFS) in addition to chemotherapy due to greater risk of recurrence in comparison to woman closer to menopause. This interview took place at the San Antonio Breast Cancer Symposium 2021 in San Antonio.
